Pharmacogenomics
A Strategic Market Outlook and Business Analysis

Table of Contents

2003

For information contact: Frontline Strategic Consulting, Inc.
1850 Gateway Drive Suite 600, San Mateo, CA 94404
650-525-1500 x135 or x145 • info@frontlinesmc.com
TABLE OF CONTENTS

I. Executive Summary
   A. Pharmacogenomics Overview
   B. Single Nucleotide Polymorphism (SNP)
   C. Historical Perspective
   D. Pharmacogenomics
      1. Definition
      2. Segments of Pharmacogenomics
   E. Worldwide Market
      3. Segment Market Growth
      5. Segment Market Projections
         a. SNP Discovery Revenues (2003E to 2008E)
         b. SNP Genotyping Revenues (2003E to 2008E)
         c. Diagnostics Revenues (2002E to 2007E)
   F. Trends, Drivers, and Bottlenecks
      1. Overview
      2. Trends in Pharmacogenomics
      3. Pharmacogenomics Market Drivers
      4. Pharmacogenomics Market Bottlenecks
   G. Strategic Analysis
      1. Overview
      2. Business Scenarios
      3. Opportunities
      4. Strategies
         a. Entry for Newcomers
         b. Growth for Existing Players
         c. Exit Strategies

II. Objectives and Methodology
    A. Report Objectives and Scope
       1. Objectives
Table of Contents

2. Scope

B. Methodology
1. Pharmacogenomics Market Model
2. Model Assumptions

C. Key Players and Strategic Analysis
1. Technology Assessment
2. Market Position
3. Comparison Parameters
   a. Comparison in 2002E

D. Data Collection
1. Primary Sources
   a. Pharmacogenomics Thought Leaders
   b. Representative Questions
2. Secondary Sources

E. Strategic Recommendations
1. Strategy Development
2. External Analysis

III. Technical Overview
A. Overview
1. Background
2. Historical Perspective
3. Scientific Background
   a. Single Nucleotide Polymorphism (SNP)
   b. Genetic Variation and Drug Response

B. Pharmacogenomics
1. Definition
2. Segments of Pharmacogenomics
   a. SNP Discovery
      i. Applied Biosystems
      ii. Celera Genomics
      iii. Incyte Genomics, Inc.
      iv. The SNP Consortium (TSC)
b. SNP Genotyping
   i. Affymetrix, Inc.
   ii. Amersham Biosciences Corp.
   iii. Genaissance Pharmaceutical, Inc.
   iv. Sequenom, Inc.
   v. Third Wave Technologies, Inc.

c. Diagnostics
   i. deCode genetics
   ii. Orchid Biosciences, Inc.
   iii. Nanogen, Inc.

IV. The Pharmacogenomics Market
   A. Worldwide Market
      3. Segment Market Growth
      5. Pharmacogenomics Companies
   B. Segment Market Projections
      1. SNP Discovery
         a. Revenues 2003E to 2008E
         b. Supplier Market Share 2003E and 2008E
         c. Supplier Competitive Analysis
            i. Positional Evaluation Bubbles (2003E)
            ii. Positional Evaluation Bubbles (2008E)
         d. Competitive Highlights
            i. Affymetrix, Inc.
            ii. Applied Biosystems
            iii. Celera
            iv. Genome Therapeutics, Inc.
            v. Incyte Genomics, Inc.
            vi. Transgenomic, Inc.
Table of Contents

2. SNP Genotyping
   a. Revenues 2003E to 2008E
   b. Supplier Market Share 2003E and 2008E
   c. Supplier Competitive Analysis
      i. Positional Evaluation Bubbles (2003E)
      ii. Positional Evaluation Bubbles (2008E)
   d. Competitive Highlights
      i. Affymetrix, Inc.
      ii. Amersham Biosciences Corp.
      iii. Applied Biosystems
      iv. Genaissance Pharmaceuticals, Inc.
      v. Orchid Biosciences, Inc.
      vi. Sequenom, Inc.
      vii. Third Wave Technologies, Inc.

3. Diagnostics
   a. Revenues 2003E to 2008E
   b. Supplier Market Share 2003E and 2008E
   c. Supplier Competitive Analysis
      i. Positional Evaluation Bubbles (2003E)
      ii. Positional Evaluation Bubbles (2008E)
   d. Competitive Highlights
      i. deCode genetics
      ii. DNA Sciences
      iii. Genaissance Pharmaceutical, Inc.
      iv. Millennium Pharmaceuticals, Inc.
      v. Nanogen, Inc.
      vi. Orchid Biosciences, Inc.

C. Technical Benefits and Limitations
   1. Overview
   2. Prevents Adverse Patient Reactions
   3. Needs Comprehensive Database
   4. Allows Effective Patient Treatment
   5. Requires Elegant Statistics
6. Assists in Drug Discovery

D. Market Model Assumptions
   1. SNP Discovery
   2. SNP Genotyping
   3. Diagnostics

V. Trends, Drivers, and Bottlenecks
   A. Overview
   B. Trends in Pharmacogenomics
      1. Overview
      2. Decreasing Interest in SNP Discovery
      3. Increasing Interest in Diagnostics
      4. Greater Variety of Technologies
      5. Adoption of Haplotypes
      6. Consolidation
   C. Pharmacogenomics Market Drivers
      1. Overview
      2. Availability of SNP Database
      3. Cost Reduction in Drug Development
      4. Greater Patient Support
      5. Increasing Number of Gene Association Studies
      6. Improved Drug Recovery
      7. Support of Healthcare Providers
   D. Pharmacogenomics Market Bottlenecks
      1. Overview
      2. Current Economic Environment
      3. Drug Sales Reduction through Segmentation
      4. Phenotype Identification
      5. SNP Pricing
Table of Contents

VI. Strategic Analysis
   A. Overview
   B. Business Scenarios
      1. Fee-for-Service
      2. Licensing Deals
      3. Alliances/Collaborations
      4. Mergers and Acquisitions
      5. Database Subscriptions
      6. Diagnostics Sales
   C. Opportunities
      1. Technical Opportunities
         a. Direct SNP Discovery Efforts
         b. Create Association Study Software
         c. Convert from High-Throughput to Clinical Application
      2. Market Opportunities
         a. Sales and Distribution Expertise
         b. Competing Drugs
   D. Strategies
      1. Entry for Newcomers
      2. Growth for Existing Players
      3. Exit Strategies

Appendix: A. Definitions
          B. Acronyms